Kevin Pojasek

Dr. Pojasek is President and acting Chief Executive Officer of Quartet Medicine, a Series A-backed start-up discovering and developing novel treatments for chronic pain and inflammation. Dr. Pojasek co-founded Quartet in late 2013 as an entrepreneur-in-residence at Atlas Venture. Dr. Pojasek is also the Chief Operating Officer of Annovation Biopharma, a clinical-stage company developing novel anesthetics in collaboration with the Medicines Company. Prior to joining Atlas in January 2013, Dr. Pojasek was Vice President of Corporate Development at Kala Pharmaceuticals, a developer of novel ophthalmology therapies, where he was responsible for the company’s corporate strategy, financing, board management, day-to-day operations, and business development activities. Dr. Pojasek joined Kala from Satori Pharmaceuticals where he oversaw the company’s development activities for the lead Alzheimer’s disease program. Prior to Satori, Dr. Pojasek co-founded and was the Executive Director of Development at Solace Pharmaceuticals where he oversaw the clinical development of the company’s lead compound, including the execution of a global Phase II neuropathic pain study. Dr. Pojasek also spent time at PureTech Ventures, an early stage venture capital firm, where he led the formation and management of several life science companies. Dr. Pojasek received his PhD from the Biological Engineering Department at MIT and his BA from the Molecular, Cellular and Developmental Biology Department at the University of Colorado, Boulder.